pI: 7.508 |
Length (AA): 382 |
MW (Da): 42136 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_128252)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G38700 | mevalonate diphosphate decarboxylase 1 |
Arabidopsis thaliana | AT3G54250 | diphosphomevalonate decarboxylase |
Brugia malayi | Bm1_42945 | diphosphomevalonate decarboxylase family protein |
Candida albicans | CaO19.13524 | diphosphomevalonate decarboxylase |
Candida albicans | CaO19.6105 | diphosphomevalonate decarboxylase |
Caenorhabditis elegans | CELE_Y48B6A.13 | Protein Y48B6A.13, isoform A |
Dictyostelium discoideum | DDB_G0278607 | diphosphomevalonate decarboxylase |
Drosophila melanogaster | Dmel_CG8239 | CG8239 gene product from transcript CG8239-RB |
Echinococcus granulosus | EgrG_000593000 | diphosphomevalonate decarboxylase |
Echinococcus multilocularis | EmuJ_000593000 | diphosphomevalonate decarboxylase |
Giardia lamblia | GL50803_23420 | Diphosphomevalonate decarboxylase |
Homo sapiens | ENSG00000167508 | mevalonate (diphospho) decarboxylase |
Leishmania braziliensis | LbrM.18.0030 | mevalonate-diphosphate decarboxylase, putative |
Leishmania donovani | LdBPK_180020.1 | diphosphomevalonate decarboxylase, putative |
Leishmania infantum | LinJ.18.0020 | mevalonate-diphosphate decarboxylase, putative |
Leishmania major | LmjF.18.0020 | mevalonate-diphosphate decarboxylase, putative |
Leishmania mexicana | LmxM.18.0020 | diphosphomevalonate decarboxylase, putative |
Loa Loa (eye worm) | LOAG_10223 | diphosphomevalonate decarboxylase |
Loa Loa (eye worm) | LOAG_07872 | hypothetical protein |
Mus musculus | ENSMUSG00000006517 | mevalonate (diphospho) decarboxylase |
Mycobacterium ulcerans | MUL_3524 | diphosphomevalonate decarboxylase |
Oryza sativa | 4328034 | Os02g0109100 |
Onchocerca volvulus | OVOC9968 |
|
Saccharomyces cerevisiae | YNR043W | diphosphomevalonate decarboxylase MVD1 |
Schistosoma japonicum | Sjp_0211750 | ko:K01597 diphosphomevalonate decarboxylase [EC4.1.1.33], putative |
Schistosoma mansoni | Smp_172660 | diphosphomevalonate decarboxylase |
Schmidtea mediterranea | mk4.002256.03 | Diphosphomevalonate decarboxylase |
Schmidtea mediterranea | mk4.072524.00 | |
Schmidtea mediterranea | mk4.063202.00 | CG5919 protein |
Trypanosoma brucei gambiense | Tbg972.10.16420 | diphosphomevalonate decarboxylase, putative |
Trypanosoma brucei gambiense | Tbg972.10.17290 | diphosphomevalonate decarboxylase, putative |
Trypanosoma brucei | Tb927.10.13560 | mevalonate-diphosphate decarboxylase |
Trypanosoma brucei | Tb927.10.14070 | mevalonate diphosphate decarboxylase |
Trypanosoma cruzi | TcCLB.511281.40 | mevalonate-diphosphate decarboxylase, putative |
Trypanosoma cruzi | TcCLB.507993.330 | mevalonate-diphosphate decarboxylase, putative |
Trichomonas vaginalis | TVAG_302660 | diphosphomevalonate decarboxylase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.13560 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.13560 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.13560 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.13560 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_Y48B6A.13 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_Y48B6A.13 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_Y48B6A.13 | Caenorhabditis elegans | larval lethal | wormbase |
CELE_Y48B6A.13 | Caenorhabditis elegans | sterile | wormbase |
YNR043W | Saccharomyces cerevisiae | inviable | yeastgenome |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.6
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Streptococcus pneumoniae serotype 2 (strain D39 / NCTC 7466) | Diphosphomevalonate decarboxylase | Compounds | References |
Homo sapiens | mevalonate (diphospho) decarboxylase | Compounds | References |
3 literature references were collected for this gene.